| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Odysight.ai Inc.
13D
ODYS · 81063V204
|
33.3% |
9/9/2026
Event 8/20/2026
|
|||
| M. Arkin (1999) Ltd. | 20.4% | ||||
| Moshe Arkin | 33.3% | ||||
|
Sol-Gel Technologies Ltd
13D/A
Amendment 7
SLGL · M8694L137
|
56.6% |
4/15/2026
Event 3/25/2026
|
|||
| Moshe Arkin | 56.6% | ||||
| M. Arkin Dermatology Ltd. | 52.4% | ||||
|
Sol-Gel Technologies Ltd
13D/A
Amendment 6
SLGL · M8694L137
|
65.3% |
6/12/2025
Event 5/29/2025
|
|||
| Moshe Arkin | 65.3% | ||||
| M. Arkin Dermatology Ltd. | 60.5% | ||||
|
Sol-Gel Technologies Ltd
13D/A
Amendment 5
SLGL · M8694L103
|
61.8% |
4/30/2025
Event 4/28/2025
|
|||
| Moshe Arkin | 61.8% | ||||
| M. Arkin Dermatology Ltd. | 60.5% | ||||
|
Odysight.ai inc
13G
ODYS · 81063V204
|
41.9% |
3/6/2025
Event 2/10/2025
|
|||
| Moshe Arkin | 41.9% | ||||
| M. Arkin (1999) Ltd. | 19.4% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.